WANKA ONLINE (01762) adopts a new equity purchase plan and grants stock options.
Wanke Yilian (01762) announces the proposal to adopt a new stock acquisition plan (Stock Acquisition Plan). The Stock Acquisition Plan aims to provide eligible participants with the opportunity to acquire ownership interests in the Company and encourages eligible participants to work towards enhancing the value of the Company and its shares for the overall benefit of the Company and its shareholders, as well as to incentivize eligible participants to contribute to the success of the Group's business. The Stock Acquisition Plan will provide the Company with a flexible method to retain, motivate, reward, thank, and compensate eligible participants and/or provide benefits to them.
WANKA ONLINE (01762) announced that the company recommends adopting a new stock purchase plan (New Stock Purchase Plan). The New Stock Purchase Plan aims to provide eligible participants with the opportunity to acquire ownership interests in the company and encourages them to work towards enhancing the value of the company and its shares for the overall benefit of the company and its shareholders, as well as to motivate eligible participants to contribute to the success of the group's business. The New Stock Purchase Plan will provide the company with a flexible way to retain, motivate, reward, thank, and compensate eligible participants and/or provide benefits to them.
On January 22, 2026, after the New Stock Purchase Plan takes effect, the board of directors recommends granting Mr. Gao Di Nan (Executive Director and Chairman of the Board), Ms. Jiang Yu (Executive Director and Chief Executive Officer), and Mr. Tong Hui (Deputy General Manager of Capital Operations Center) with 50 million stock options, 50 million stock options, and 60 million stock options respectively.
Related Articles

LINGBAO GOLD (03330): Huang Hui appointed as independent non-executive director.

LEADS BIOLABS-B(09887): Vitrakvi has been granted orphan drug designation (ODD) by the European Commission for the treatment of pulmonary neuroendocrine tumors.

MACAU LEGEND (01680) raised approximately HK$86.4 million from the issuance of new shares.
LINGBAO GOLD (03330): Huang Hui appointed as independent non-executive director.

LEADS BIOLABS-B(09887): Vitrakvi has been granted orphan drug designation (ODD) by the European Commission for the treatment of pulmonary neuroendocrine tumors.

MACAU LEGEND (01680) raised approximately HK$86.4 million from the issuance of new shares.

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


